Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Исследование эффективности применения генерического розувастатина при цереброваскулярных заболеваниях*
Исследование эффективности применения генерического розувастатина при цереброваскулярных заболеваниях*
Ласло Сапари, Гергей Фехер. Исследование эффективности применения генерического розувастатина при цереброваскулярных заболеваниях*. Consilium Medicum. 2014; 16 (5): 71–73.
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Полный текст
Список литературы
1. Lewington S, Whitlock G, Clarke R et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a metaanalysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 2007; 370: 1829–39.
2. Cobain MR, Pencina MJ, D’Agostino RB Sr et al. Lifetime risk for developing dyslipidemia: the Framingham Offspring Study. Am J Med 2007; 120: 623–30.
3. Mills EJ, Rachlis B, Wu P et al. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol 2008; 52: 1769–81.
4. Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol 2009; 8: 453–63.
5. Fehér G. Statin therapy in patients with cerebrovascular disorders. [Statinkezelés cerebrovascularis betegekben.] Hááziorvos Tovébbkápző Szemle 2009; 14: 519–25.
6. Feher A, Pusch G, Koltai K et al. Statintherapy in the primary and the secondary prevention of ischaemic cerebrovascular diseases. Int J Cardiol 2011; 148: 131–8.
7. http://www.webbeteg.hu/cikkek/jogi_esetek/1385/generikuskontra-originalis-gyogyszerek [Hungarian].
8. Feher A, Pusch G, Harang G et al. Generic statins in cardiovascular medicine. J Bioequiv Availab 2012. Doi: 10.4172/ jbb.S2-003
9. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011; 32: 1769–818.
10. Kesselheim AS, Misono AS, Lee JL et al. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. JAMA 2008; 300: 2514–26.
11. Crouse JR 3rd, Raichlen JS, Riley WA et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA 2007; 297:
1344–53.
12. Kostapanos MS, Elisaf MS. JUPITER and satellites: Clinical implications of the JUPITER study and its secondary analyses. World J Cardiol 2011; 3: 207–14.
13. Jafri H, Alsheikh-Ali AA, Karas RH. Meta-analysis: statin therapy does not alter the association between low levels of high-density lipoprotein cholesterol and increased cardiovascular risk. Ann Intern Med 2010; 153: 800–8.
14. Kostapanos MS, Milionis HJ, Elisaf MS. Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia. Am J Cardiovasc Drugs 2010; 10: 11–28.
2. Cobain MR, Pencina MJ, D’Agostino RB Sr et al. Lifetime risk for developing dyslipidemia: the Framingham Offspring Study. Am J Med 2007; 120: 623–30.
3. Mills EJ, Rachlis B, Wu P et al. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol 2008; 52: 1769–81.
4. Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol 2009; 8: 453–63.
5. Fehér G. Statin therapy in patients with cerebrovascular disorders. [Statinkezelés cerebrovascularis betegekben.] Hááziorvos Tovébbkápző Szemle 2009; 14: 519–25.
6. Feher A, Pusch G, Koltai K et al. Statintherapy in the primary and the secondary prevention of ischaemic cerebrovascular diseases. Int J Cardiol 2011; 148: 131–8.
7. http://www.webbeteg.hu/cikkek/jogi_esetek/1385/generikuskontra-originalis-gyogyszerek [Hungarian].
8. Feher A, Pusch G, Harang G et al. Generic statins in cardiovascular medicine. J Bioequiv Availab 2012. Doi: 10.4172/ jbb.S2-003
9. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011; 32: 1769–818.
10. Kesselheim AS, Misono AS, Lee JL et al. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. JAMA 2008; 300: 2514–26.
11. Crouse JR 3rd, Raichlen JS, Riley WA et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA 2007; 297:
1344–53.
12. Kostapanos MS, Elisaf MS. JUPITER and satellites: Clinical implications of the JUPITER study and its secondary analyses. World J Cardiol 2011; 3: 207–14.
13. Jafri H, Alsheikh-Ali AA, Karas RH. Meta-analysis: statin therapy does not alter the association between low levels of high-density lipoprotein cholesterol and increased cardiovascular risk. Ann Intern Med 2010; 153: 800–8.
14. Kostapanos MS, Milionis HJ, Elisaf MS. Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia. Am J Cardiovasc Drugs 2010; 10: 11–28.
Авторы
Ласло Сапари, Гергей Фехер
Кафедра общей медицины Печского университета, Венгрия;
Неврологическая клиника, г. Печ, Венгрия
Кафедра общей медицины Печского университета, Венгрия;
Неврологическая клиника, г. Печ, Венгрия
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.